General
Preferred name
ERIBULIN
Synonyms
ER-086526 ()
E7389 ()
B1939 ()
B1939 mesylate ()
ER-086526 mesylate ()
E7389 mesylate ()
ERIBULIN MESYLATE ()
Halaven ()
Eribulin (mesylate) ()
B1939 (mesylate) ()
E7389 (mesylate) ()
ER-086526 (mesylate) ()
E-7389 FREE BASE ()
Eribuline ()
Eribulina ()
B-1939 ()
E-7389 ()
NSC-707389 ()
Eribulin monomethanesulfonate ()
Eribulin (as mesylate) ()
Mevlyq ()
Eribulin baxter ()
Eribulin mesilate ()
P&D ID
PD052173
CAS
253128-41-5
441045-17-6
Tags
available
drug
Approved by
EMA
FDA
First approval
2010
Drug indication
Neoplasm
Bladder cancer
breast carcinoma
Breast cancer
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
A pan tubulin inhibitor which is a fully synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B (a mitosis inhibitor). Marketed formulations may contain eribulin mesylate (PubChem CID 17755248).
(GtoPdb)
DESCRIPTION
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
PRICE
951
PRICE
1002
DESCRIPTION
Eribulin (B1939) is a nonpaclitaxel microtubule kinetic inhibitor with anticancer activity that inhibits polymerization of microtubule protein subunits by preventing lengthening and shortening of microtubules during cell division.Eribulin is used in the study of metastatic breast cancer and solid tumors.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Eribulin mesylate (E7389 mesylate) (E7389 mesylate) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used in the treatment of metastatic breast cancer.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
4
Organisms
0
Compound Sets
21
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
234
Molecular Weight
729.41
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
10
Aromatic Ring Count
0
cLogP
3.44
TPSA
146.39
Fraction CSP3
0.88
Chiral centers
19.0
Largest ring
22.0
QED
0.41
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Microtubule
Apoptosis
Microtubule/Tubulin
ADC Payloads
ADC Cytotoxin
Indication
breast cancer
MOA
microtubule inhibitor
Biosynthetic Origin
Polyketide
Therapeutic Indication
Anticancer
Pathway
Cell Cycle/DNA Damage
cytoskeleton
Antibody-drug Conjugate/ADC Related
Cytoskeletal Signaling
Source data

